Bernardo Arias, MD
Psychiatry · Port Charlotte, FLNPI 1912992132
Payments from drug & device makers
Across 982 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lundbeck LLC$2K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- Johnson & Johnson$1K
- plus $9K from 27 others
What the payments were for
- Food & beverage$17,91599%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 135 | $2,099 |
| Lundbeck LLC | 75 | $1,578 |
| Otsuka America Pharmaceutical, Inc. | 83 | $1,436 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 92 | $1,388 |
| Alkermes, Inc. | 69 | $1,358 |
| Johnson & Johnson | 46 | $1,273 |
| Vanda Pharmaceuticals Inc. | 45 | $1,254 |
| Corium, LLC | 53 | $949 |
| Neurocrine Biosciences, Inc. | 45 | $899 |
| Tris Pharma Inc | 62 | $760 |
| Ironshore Pharmaceuticals Inc. | 39 | $732 |
| Teva Pharmaceuticals USA, Inc. | 30 | $651 |
| Axsome Therapeutics, Inc. | 22 | $443 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $433 |
| Merck | 21 | $409 |
| Indivior Inc. | 17 | $339 |
| Almatica Pharma LLC | 17 | $285 |
| Supernus Pharmaceuticals, Inc. | 18 | $275 |
| Jazz Pharmaceuticals Inc. | 15 | $247 |
| E.r. Squibb & Sons, L.L.C. | 15 | $224 |
| Collegium Pharmaceutical, Inc. | 11 | $187 |
| Noven Therapeutics, LLC | 12 | $170 |
| Adlon Therapeutics L.p. | 9 | $158 |
| Idorsia Pharmaceuticals US Inc | 7 | $123 |
| Neuronetics, Inc. | 5 | $101 |
| Eisai Inc. | 3 | $47 |
| Shire North American Group Inc | 3 | $47 |
| Braeburn Inc. | 2 | $45 |
| Neos Therapeutics, LP | 2 | $38 |
| Boston Scientific | 1 | $26 |
| Livanova USA, Inc. | 1 | $21 |
| Tempus AI, Inc | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$128
- Jornay PM 20mg capsules (Bottle of 100)$125
- Azstarys$104
- CAPLYTA$100
How this compares
$18,022 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 46 | $154,254 |
| VraylarCariprazine Hcl | 67 | $121,909 |
| RexultiBrexpiprazole | 47 | $86,070 |
| TrintellixVortioxetine Hydrobromide | 73 | $59,455 |
| VyvanseLisdexamfetamine Dimesylate | 40 | $19,820 |
| Quetiapine Fumarate | 568 | $16,338 |
| Divalproex Sodium ErDivalproex Sodium | 210 | $11,950 |
| Aripiprazole | 274 | $11,136 |
| Duloxetine Hcl | 342 | $9,663 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 70 | $8,954 |
| Clonazepam | 580 | $7,287 |
| Rivastigmine | 28 | $6,183 |
| Lisdexamfetamine Dimesylate | 25 | $6,154 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 59 | $5,859 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 123 | $5,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,273 | $154,25446 claims |
| AbbVieVraylar | $2,099 | $121,90967 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,436 | $86,07047 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $433 | $79,275113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Port Charlotte
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.